Atreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of Malaria
21 10월 2021 - 9:00PM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that it has entered into a licensing agreement with the Bill &
Melinda Gates Medical Research Institute (the “Institute” or “Gates
MRI”) to develop MAM01/ATRC-501, a novel monoclonal antibody
entering preclinical development, for the prevention of malaria.
Under the agreement, Gates MRI will lead the development of
MAM01/ATRC-501 and receive commercial rights in GAVI-eligible
countries located in malaria-endemic regions of the world, to
advance its charitable purposes. Atreca will retain commercial
rights in the U.S., Europe and parts of Asia.
Malaria is a life-threatening, mosquito-borne disease that
impacts regions of Central and South America, Africa, South and
Southeast Asia, the Caribbean, the Middle East and Oceania with
more than 94% of worldwide malaria cases and deaths occurring in
the World Health Organization’s (WHO) African Region. Despite
multiple public health interventions, there were an estimated 229
million malaria cases and over 400,000 deaths in 2019 according to
WHO1. Further reducing the global malaria burden will require the
development and implementation of new prevention strategies,
including the use of vaccines such as Mosquirix™ and antibody-based
prophylaxis currently under development. To that end, a clinical
study from the National Institutes of Health (NIH) recently
published in the New England Journal of Medicine demonstrated that
an antibody administered to healthy human adults can potentially
prevent infection2. These data provide first proof of concept that
an antibody-based prophylactic may protect humans against malaria
infection for a period of time after dosing.
MAM01/ATRC-501 is an engineered version of a human monoclonal
antibody generated following vaccination with Mosquirix™ and
identified via Atreca’s discovery platform. MAM01/ATRC-501 targets
the malaria circumsporozoite protein (CSP) and has been shown to
protect animals against malaria infection in multiple in vivo mouse
studies.
Gates MRI plans to undertake development efforts for
MAM01/ATRC-501 for prevention of malaria in infant and pediatric
populations in malaria endemic regions. Potential product
development opportunities for Atreca include prevention of malaria
for those traveling to regions where malaria may be circulating.
Current malaria prophylaxis agents for travelers are small molecule
drugs that can be poorly tolerated and require repeat dosing, which
may lead to suboptimal compliance.
“Today’s announcement is the result of an extensive
collaboration to identify protective antibodies against malaria
that we initiated with the Bill & Melinda Gates Foundation in
2013 and which has involved multiple research organizations and
academic institutions as collaborators,” said John Orwin, President
and CEO of Atreca. “We are excited that the Institute has decided
to move forward with the development of MAM01/ATRC-501. While our
current drug discovery efforts focus on oncology, malaria
prevention remains a major unmet medical need, and we are proud and
gratified to be collaborating with the Institute on a potential
antibody-based prophylactic.”
“Tackling the public health challenges posed by malaria is a
priority for our Institute,” said Emilio Emini Ph.D., CEO of the
Bill & Melinda Gates Medical Research Institute. “We are
pleased to enter into this agreement for Atreca’s potential
antibody prophylactic intervention that could provide prolonged
protection against malaria infection.”
References
-
https://www.who.int/news-room/fact-sheets/detail/malaria
- Gaudinski et al, 2021 NEJM.
https://www.nejm.org/doi/full/10.1056/NEJMoa2034031
About Atreca, Inc.Atreca is a biopharmaceutical
company developing novel antibody-based immunotherapeutics
generated by its differentiated discovery platform. Atreca's
platform allows access to an unexplored landscape in oncology
through the identification of unique antibody-target pairs
generated by the human immune system during an active immune
response against tumors. These antibodies provide the basis for
first-in-class therapeutic candidates, such as our lead product
candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in
multiple solid tumor cancers is currently enrolling patients. For
more information on Atreca, please visit www.atreca.com.
Atreca Forward-Looking StatementsStatements
contained in this press release regarding matters that are not
historical facts are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and typically are identified by use of terms such as
“continued,” “anticipate,” “potential,” “expect,” “believe,”
“planned,” and similar words, although some forward-looking
statements are expressed differently. These statements include
those related to our strategy and future plans, including
statements regarding the development of MAM01/ATRC-501, including
its product development opportunities for prevention of malaria for
those traveling to malaria regions, the potential for an
antibody-based prophylactic to protect humans against malaria for a
period of time after dosing, the potential suboptimal compliance
with current malaria prophylaxis, the development of ATRC-101, and
our preclinical, clinical and regulatory plans and the timing
thereof. Our actual results may differ materially from those
indicated in these forward-looking statements due to risks and
uncertainties related to the initiation, timing, progress and
results of our research and development programs, preclinical
studies, clinical trials, regulatory submissions, and other matters
that are described in our filings with the Securities and Exchange
Commission (SEC) and available on the SEC’s website
at www.sec.gov, including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of our most recently filed annual
report on Form 10-K and quarterly report on Form 10-Q. Investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release,
and we undertake no obligation to update any forward-looking
statement in this press release, except as required by law.
Contacts
Atreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray,
650-779-9251agray@atreca.com
Media:Rachel Ford Hutman,
301-801-5540Rachel@fordhutmanmedia.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024